Aggressive cholesterol management may need redefinition as emerging evidence suggests cardiovascular benefits extend well below current clinical targets. This paradigm challenges the traditional "good enough" approach to LDL reduction in high-risk patients. The latest large-scale clinical evidence demonstrates that pushing LDL cholesterol levels substantially below the standard 70 mg/dL target—down to 55 mg/dL or lower—produces measurable reductions in major cardiovascular events among patients with established atherosclerotic disease. The intensive treatment protocol achieved these ultra-low levels through combination lipid-lowering therapy, typically pairing high-intensity statins with newer agents like PCSK9 inhibitors or ezetimibe. Participants receiving intensive targeting experienced statistically significant decreases in heart attacks, strokes, and cardiovascular deaths compared to those maintained at conventional LDL targets. The benefit appeared consistent across different patient subgroups, including those with diabetes and varying baseline risk profiles. This finding aligns with decades of observational data showing that populations with genetically low LDL levels experience remarkably low cardiovascular disease rates throughout their lifespans. However, the practical implementation faces significant barriers. The intensive protocols require expensive newer medications that many insurance systems resist covering. Safety monitoring becomes more complex, particularly regarding potential muscle-related side effects from combination therapy. Additionally, the absolute risk reduction, while statistically significant, remains modest—meaning many patients must be treated intensively to prevent one additional event. The clinical community now grapples with whether these incremental gains justify the increased complexity and cost, especially given that lifestyle interventions and moderate statin therapy already provide substantial cardiovascular protection for most patients.